Form 4: ImmunityBio Director Sells Shares Under 10b5-1 Plan

ImmunityBio Director Barry J. Simon reported the sale of 151,967 shares of common stock on January 20, 2026, executed under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Barry J. Simon, a Director of ImmunityBio, Inc. (IBRX), reported the disposition of common stock.
• On January 20, 2026, a total of 151,967 shares of common stock were sold in two separate transactions.
• The first transaction involved the sale of 76,967 shares at a price of $6.54 per share.
• The second transaction involved the sale of 75,000 shares at a weighted average price of $7.8791 per share, with prices ranging from $7.87 to $7.8950.
• These sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Simon on September 4, 2024.
• Following these transactions, Mr. Simon beneficially owns 3,091,604 shares of ImmunityBio common stock.
• A Power of Attorney, executed on October 30, 2025, authorizes designated individuals to prepare and file SEC reports on behalf of Mr. Simon.

Sentiment

Score: 5

Explanation: The filing reports a pre-scheduled insider stock sale under a Rule 10b5-1 plan, which typically indicates a neutral event as the decision to sell was made in advance of the transaction date. While it represents a reduction in insider holdings, the pre-planned nature mitigates immediate negative sentiment.

Stakeholder Impact

• Shareholders may note the reduction in a director's direct beneficial ownership, although the pre-planned nature of the sale under Rule 10b5-1 typically reduces concerns about opportunistic selling.

Key Dates

Recommendation

The reported transactions are insider sales executed under a Rule 10b5-1 trading plan, which was adopted several months prior to the sales. Such pre-arranged plans are designed to allow insiders to sell shares without being accused of trading on material non-public information. While a director selling shares might typically be viewed negatively, the 10b5-1 plan context suggests a planned liquidity event rather than a reaction to new, adverse company developments. Therefore, this filing alone does not provide a strong signal for a 'buy' or 'sell' recommendation, warranting a 'hold' as investors should look to broader company fundamentals and market conditions.

Keywords

ImmunityBio, IBRX, Form 4, Insider Trading, Stock Sale, Director, 10b5-1 Plan, Equity Disposition